Daporinad

Overview

Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase ( Nampt ), with a K i value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy . Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis , and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer , and immunosuppression.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > ERK | Products > Signaling Pathways > NAMPT | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-50876
• CAS No.: 658084-64-1
• Molecular Formula: C24H29N3O2
• Molecular Weight: 391.51
• Purity: 99.91%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution
• Availability: In-stock

Source

Original product source